BUZZ-Palisade Bio rises; bowel disease drug set for global conference spotlight

Reuters01-16
BUZZ-<a href="https://laohu8.com/S/PALI">Palisade Bio</a> rises; bowel disease drug set for global conference spotlight

** Shares of drug developer Palisade Bio PALI.O rise 1.7% to $1.78 premarket

** Co says its experimental ulcerative colitis drug, PALI‑2108, is set to be featured at two major medical conferences next year

** Ulcerative colitis is a chronic bowel disease that causes inflammation and bleeding in the colon

** PALI says early‑stage data shows all patients responded with no serious safety issues

** Presentations are planned for the Crohn’s & Colitis Congress in Las Vegas and the European Crohn’s and Colitis Organisation Congress in Stockholm - PALI

** Says it is preparing a larger 12‑week study and planning Crohn’s disease research

** As of last close, stock up ~42% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment